vimarsana.com

Page 26 - பல்கலைக்கழகம் ஆஃப் தெற்கு டென்மார்க் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Single-use face masks are a ticking time bomb of global pollution, experts warn

Princeton University, and Elvis Xu, an environmental scientist from the  Based on recent studies, the authors estimated that some 129 billion single-use face masks are used per month worldwide. This figure corresponds to three million masks used per minute. Most of these masks are made from plastic microfibers, typically ranging in size from five millimeters (mm) to microscopic lengths. There have been increasing reports as well of the inappropriate disposal of soiled face masks. The authors said it is urgent to recognize single-use face masks as a potential environmental threat to prevent them from becoming the next big plastic problem. Face masks could be worse than plastic bottles

Major Danish-Norwegian Study Concludes Benefits of AstraZeneca Vaccine Outweigh Risks

Major Danish-Norwegian Study Concludes Benefits of AstraZeneca Vaccine Outweigh Risks © REUTERS / YVES HERMAN Subscribe Sputnik International https://sputniknews.com/europe/202105071082822687-major-danish-norwegian-study-concludes-benefits-of-astrazeneca-vaccine-outweigh-risks/ Despite patients potentially facing a higher risk of thrombosis than initially expected, the researchers described the results “generally reassuring” and found the debated vaccine to yield a net gain, both at the level of society and at the individual level. A study of Danish and Norwegian residents who have been administered the AstraZeneca vaccine has concluded that the benefits of the shot still outweigh the risks. The study by researchers at the University of Southern Denmark and at the Norwegian Institute of Public Health, the most comprehensive and systematic in both countries to date, found that vaccine recipients faced a one in 40,000 risk of get

New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events low

›New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events low New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events low SECTIONS New study finds slightly increased rates of vein blood clots after AstraZaneca Covid vaccine; stresses risk of adverse events lowPTI Last Updated: May 07, 2021, 05:35 PM IST Share Synopsis The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca vaccine. iStock Related NEW DELHI: A large study in Denmark and Norway has found slightly increased rates of vein blood clots, including in the brain, among adults who had received their first dose of the Oxford-AstraZeneca COVID-19 vaccine, compared with expected rates in the general population. However, the study published in The BMJ on Wednesday, stresses that the risk of such adverse events is considered low.

Study finds slightly increased blood clot rates after AstraZaneca COVID-19 shot

The findings are based on 280,000 people aged 18-65 who received a first dose of the Oxford-AstraZeneca COVID-19 vaccine, known as Covishield in India, from February 2021 through to 11 March 2021 in Denmark and Norway. Using national health records, they identified rates of events, such as heart attacks, strokes, deep vein blood clots and bleeding events within 28 days of receiving a first vaccine dose and The researchers found 59 blood clots in the veins compared with 30 expected, corresponding to 11 excess events per 100,000 vaccinations. This included a higher than expected rate of blood clots in the veins of the brain, known as cerebral venous thrombosis (2.5 events per 100,000 vaccinations), the said.

New study documents possible adverse events in relation to Vaxzevria COVID-19 vaccine

New study documents possible adverse events in relation to Vaxzevria COVID-19 vaccine The new Danish-Norwegian study is the first study to document possible adverse events in relation to the COVID-19 vaccine Vaxzevria from AstraZeneca, in which all vaccine recipients have been followed systematically, as opposed to previous studies, which have relied primarily on reported adverse reactions. The new study was a cooperation between Danish and Norwegian research institutions. - In this study, we were able to identify all hospital contacts among vaccinated persons by utilising the unique Danish and Norwegian health registers. This ensures that we get a comprehensive of the rate of adverse reactions. Previous studies have been dependent on spontaneous reporting of adverse events in individual patients, which carries a risk of under-reporting, says Anton Pottegård, who is a professor at the University of Southern Denmark and co-author of the study.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.